References
- Reszke R, Szepietowski JC. Secukinumab in the treatment of psoriasis: an update. Immunotherapy. 2017;9:229–238.
- Ryoo JY, Yang HJ, Ji E, et al. Meta-analysis of the efficacy and safety of secukinumab for the treatment of plaque psoriasis. Ann Pharmacother. 2016;50:341–351.
- Garnock-Jones KP. Secukinumab: a review in moderate to severe plaque psoriasis. Am J Clin Dermatol. 2015;16:323–330.
- Rich P, Sigurgeirsson B, Thaci D, et al. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study. Br J Dermatol. 2013;168:402–411.
- Lebwohl M, Qureshi A, Kianifard F. Secukinumab in the treatment of moderate to severe scalp psoriasis: a study to evaluate efficacy and safety. J Am Acad Dermatol. 2015;72:AB250.
- Burkett PR, Kuchroo VK. IL-17 Blockade in psoriasis. Cell. 2016;167:1669.